Infectious Disease Molecular Diagnostics Market to 2032: Advanced R&D Process StrategiesPosted by Ganesh Shinde on January 18th, 2023  In 2021, the global Infectious Disease Molecular Diagnostics Market was estimated to be worth approximately US$ 34 billion. With a projected CAGR of 4.2% over the next ten years, the market is expected to be worth nearly US$ 53 billion by the end of 2032. Rather than the traditional methods that required pathogen culture, developers are increasingly relying on scientific developments from a variety of fields. Molecular diagnostics is one of the fastest growing fields in infectious disease identification. Global outbreaks of deadly infectious diseases caused by pathogenic microorganisms have significantly motivated researchers to develop rapid and accurate pathogen detection methods. Culture-based techniques are widely regarded as the gold standard for pathogen detection around the world. However, due to overnight culturing and limited pathogen isolation, the long result time associated with these techniques has slowed their demand to some extent. Over the last few years, advances in molecular diagnostic technology and their application have fundamentally altered our ability to treat infectious diseases. It provides customers with faster and more reliable results at a 30% lower cost. Infectious Diseases Molecular Diagnostics Market: Segmentation Valuable information covered in the FMI’s Infectious Diseases Molecular Diagnostics market report has been segregated into key segments and sub-segments. By Technology:
By Product Type:
By End Use:
By Application:
Browse More@ https://www.futuremarketinsights.com/reports/infectious-diseases-molecular-diagnostics-market Key players covered in the report include: F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Abbott Laboratories, bioMérieux SA, QIAGEN N.V., Myriad Genetics, Inc., Siemens Healthineers AG, Danaher Corporation, Illumina, Inc., Others Like it? Share it! More by this author |